Bennett C Frank's Form 4/A amendment
AmendedIonis Pharmaceuticals Inc (IONS) · filed Feb 13, 2026
- Accession no.
- 0000874015-26-000112
- Filed
- Feb 13, 2026
- Trade date
- Feb 2, 2026
- Filing delay
- 11 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Feb 4, 2026
This filing lists 1 non-derivative transaction. It carries over 7 transactions from the original filing that it did not restate. Open-market sales total $7.06M. It was filed 11 days after the trade.
This amendment restates part of 0000874015-26-000104 (filed Feb 4, 2026). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bennett C FrankCIK 0001073387 | Officer (EVP, Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Common Stock | JOtherDisposed | 0 | $0.00 | $0 | 100,293 | Direct |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0000874015-26-000104 (filed Feb 4, 2026).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Common Stock | SSaleDisposed | −20,000 | $82.60F1 | −$1,652,000 | 80,293 | Direct | |
| Feb 2, 2026 | Common Stock | MOption exerciseAcquired | +48,626 | $60.89 | +$2,960,837.14 | 128,919 | Direct | |
| Feb 2, 2026 | Common Stock | SSaleDisposed | −48,626 | $83.03F2 | −$4,037,416.78 | 80,293 | Direct | |
| Feb 2, 2026 | Common Stock | MOption exerciseAcquired | +16,463 | $32.60 | +$536,693.8 | 96,756 | Direct | |
| Feb 2, 2026 | Common Stock | SSaleDisposed | −16,463 | $83.03F2 | −$1,366,922.89 | 80,293 | Direct |
Derivative securities (Table II)
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Common Stock | MOption exerciseDisposed | −16,463 | $0.00 | $0 | 2,406 | Direct | |
| Feb 2, 2026 | Common Stock | MOption exerciseDisposed | −48,626 | $0.00 | $0 | 0 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.92 to $82.775 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.775 to $83.34 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
Referenced by the price of 2 transactions in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On February 4, 2026, the reporting person filed a Form 4 reporting the sale of 20,000 shares of common stock and the exercise of 65,089 stock options, which transactions were executed in error and subsequently reversed on February 12, 2026. Shares beneficially owned by the reporting person as of February 12, 2026 is 100,293.